Tumor hypoxia and gene expression - Implications for malignant progression and therapy

Acta Oncologica

Volumn 37, Issue 6, 1998, Pages 567-574

  Sutherland, Robert M ^a  

^a Varian Biosynergy Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CELL HETEROGENEITY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; HYPOXIC CELL; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0031735450     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430278     Document Type: Article

References (72)

1. Vaupel PW. Oxygenation of solid tumors. In: Teicher BA, ed. Drug resistance in oncology. New York: Marcel Dekker, Inc, 1993: 59-85.
2. Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors: correlation between methods of measurement and response to therapy. Radiat Res 1993; 136: 422-34.
3. Raleigh J, Dewhirst M, Thrall D. Measuring tumor hypoxia. Semin Radiat Oncol 1996; 6: 37-45.
4. 2 tension measurements. Cancer Res 1991; 51: 3316-22.
5. Höckel M, Vorndran B, Schlenger K, et al. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993; 51: 141-9.
6. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
7. Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 1996; 6: 3-9.
8. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of head and neck. Radiother Oncol 1996; 41: 31-9.
9. Vaupel P. Oxygenation of human tumors: current status of knowledge. Abstract from Tumor Microenvironment Meeting. Martha's Vineyard, 1997.
10. Kolstad P. Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest 1968; 106 (Suppl): 145-57.
11. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Rad Oncol Biol Phys 1988; 14: 831-8.
12. Brizel DM, Sibley GS, Prosmitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-9.
13. Brizel DW, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-3.
14. Nordsmark M, Overgaard J. Hypoxia in human tumors and clinical outcome, Abstract from Tumor Microenvironment Meeting. Martha's Vineyard, 1997.
15. Bush RS, Jenkin RDT, Allt WEC, et al. Definite evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978; 37: 302-6.
16. Schwickert G, Walenta S, Sundfør K, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 1995; 55: 4757-9.
17. Walenta S, Salameh A, Lyng et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Path 1997; 150:409-15.
18. Stoler DL, Anderson GR, Russo CA, Spina AM, Beerman TA, Anoxia-inducible endonuclease activity as a potential basis of the genomic instability of cancer cells. Cancer Res 1992; 52: 4372-8.
19. Reynolds T, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56: 5754-7.
20. Sutherland RM, Ausserer WA, Murphy BJ, Laderoute KR. Tumor hypoxia and heterogeneity: challenges and opportunities for the future. Semin Rad Oncol 1996; 6: 59-70.
21. Ausserer WA, Bourrat-Floeck B, Green CJ, et al. Regulation of c-jun expression during hypoxic and low-glucose stress. Mol Cell Biol 1994; 14: 5032-42.
22. Yao K-S, Xanthoudakis S, Curran T, O'Dwyer PJ. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol 1994; 14: 5997-6003.
23. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6264-77.
24. Kastan MB, Onyekwere O, Sidreansky D, et al. Participation of p53 in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
25. Kastan MB, Zhan Q, El-Diery W, et al. A mammalian cell-cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-97.
26. Fornace AJ Jr, Nebert DW, Hollander MC, et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Molecular Cell Biol 1989; 9: 4196-203.
27. Giaccia AJ. Hypoxic stress proteins: survival of the fittest. Semin Radiat Oncol 1996; 6: 46-58.
28. Lowe SW, Ruley HE, Jacks T, et al. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
29. Lowe SW, Jacks T, Housman DE, et al. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 1994; 91: 2026-30.
30. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
31. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (Lond) 1996; 379: 88-91.
32. Kim CY, Tsai MH, Osmanian C, et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 1997; 57: 4200-4.
33. Shweiki D, Itrin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-mediated angiogenesis. Nature 1992; 349: 843-5.
34. Shweiki D, Neeman M, Itin A, et al. Induction of vascular endothelial growth factor expression by hypoxia and by tumor angiogenesis. Proc Natl Acad Sci USA 1995; 92: 768-72.
35. Waleh NS, Brody MD, Knapp MA, et al. Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia specific marker. Cancer Res 1995; 55: 6222-6.
36. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-87.
37. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-9.
38. Giaccia AJ, Alarcon RM, Brody M. The influence of hypoxia on positive and negative regulators of angiogenesis: in vitro and in vivo studies. Abstract from Tumor Microenvironment Meeting. Martha's Vineyard, 1997.
39. Agani F, Kirsch DG, Friedman SL, Kastan MB, Semenza GL. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res 1997; 57: 4474-7.
40. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-54.
41. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-7.
42. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity of hypoxia. J Biol Chem 1993; 268: 21513-8.
43. Firth JD, Ebert BL, Pugh CW, et al. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994; 91: 6496-500.
44. Semenza GL, Roth PH, Fang HM, et al. Transcriptional regulation of genes encoding glycolytic enzymes of hypoxia-inducible factor 1. J Biol Chem 1994; 269: 23757-63.
45. Forsythe JA, Jiang B-H, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
46. Mazure NM, Chen KY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996; 56: 3436-40.
47. Jiang B-H, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-35.
48. Laderoute KR, Grant TD, Murphy BJ, Sutherland RM. Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int J Cancer 1992; 52: 428-32.
49. Heacock CS, Sutherland RM. Enhanced synthesis of stress proteins caused by hypoxia and relation to altered cell growth and metabolism. Br J Cancer 1990; 62: 217-25.
50. Murphy BJ, Laderoute KR, Short SM, et al. The identification of heme oxygenase as a major hypoxic stress protein in Chinese hamster ovary cells. Br J Cancer 1991; 64: 69-73.
51. O'Dwyer PJ, Yao K-S, Ford P, Godwin AK, Clayton M. Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. Cancer Res 1994; 54: 3082-7.
52. Murphy BJ, Laderoute KR, Chin RJ, et al. Metallothionein IIA is up-regulated by hypoxia in human A431 squamous carcinoma cells. Cancer Res 1994; 54: 5808-10.
53. Murphy BJ, Andrews GK, Bittel D et al. Activation of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1 (In press, 1998).
54. Kelly SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-5.
55. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 242: 1412-5.
56. Acker H. Mechanism and meaning of cellular oxygen sensing in the organism. Respir Physiol 1994; 95: 1-10.
57. Koong AC, Chen KY, Mivechi NF, et al. Hypoxia activation of nuclear factor-kB is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res 1994; 54: 5273-9.
58. Koong AC, Chen EY, Kim CY, et al. Activators of protein kinase c selectively mediate cellular cytotoxicity to hypoxic cells and not aerobic cells. Int J Radiat Oncol Biol Phys 1994; 29: 259-65.
59. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor kB though the phosphorylation of IkBα on tyrosine residues. Cancer Res 1994; 54: 1425-30.
60. Mazure NM, Chen EY, Laderoute ER, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90: 3322-31.
61. Abate CL, Patel L, Rauscher FJ, et al. Redox regulation of Fos and Jun DNA-binding activity in vitro. Science 1990; 249: 1157-61.
62. Zeng J, Heuchel R, Schaffner W, et al. Thionein can modulate DNA binding and transcription activation by zinc finger containing factor Sp1. FEBS Lett 1991; 279: 310-2.
63. Knoepfel L, Steinkuhler C, Carri M, et al. Role of zinc-coordination and the glutathione redox couple in the redox susceptibility of human transcription factor Sp1. Biochem Biophys Res Commun 1994; 201: 871-7.
64. Powis G, Briehl M, Oblong J. Redox signaling and the control of cell growth and death. Pharmac Ther 1995; 68: 149-73.
65. Berggren M, Gallegos A, Gasdaska PY, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum starvation and hypoxia. Anticancer Res 1996; 16: 3459-66.
66. Wu X, Bishophric NH, Discher DJ, Murphy BJ, Webster KA. Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol Cell Biol 1996; 16: 1035-46.
67. Laderoute KR, Calaoagan JM, Mendonca HL. Early response of SiHa human squamous carcinoma cells to hypoxic signals: evidence of parallel activation of NF-kB and AP-1 transcriptional complexes. Intl J Oncol 1996; 8: 857-82.
68. Laderoute KR, Mendonca HL, Calaoagan JM, Knapp AM, Giaccia AJ, Sutherland RM. Induction of p38 kinase and SAPK/JNK pathways in hypoxic tumor cells. Abstract from Tumor Microenvironment Meeting. Martha's Vineyard, 1997.
69. Chen Y-R, Wang X, Templeton D, Davis RJ, Tan T-H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and γ radiation. J Biol Chem 1996; 271: 31929-36.
70. Kyriakis JM, Avruch J. Sounding the alarm - protein-kinase cascades activated by stress and inflammation. J Biol Chem 1996; 271: 24313-6.
71. Brown JM, Siim BG. Hypoxia-specific cytotoxins in cancer therapy. Semin Rad Oncol 1996; 6: 22-36.
72. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nature Med 1997; 3: 515-20.